

* * * Personal Journal (30.Mar. 2017 11:37) * * *

1)
2)

(Manual print)

< TX >										File
Date	Time	Destination	Mode	TXtime	Page	Result	User Name			No.
30. Mar.	10:30	001912226598120	G3TESM	0'36"	P.	1 E				0486
	10:38	001912226598120	G3TESM	1'05"	P.	1 E				0486
	10:44	001912226598120	G3TESM	2'55"	P.	3 OK				0486

< RX >										File
Date	Time	Sender	Mode	RXtime	Page	Result	User Name			No.

TX Count

000491

: Batch
M : Memory
S : Standard
> : Reduction
Q : RX Notice Req.
<-> : IP-FAX

C : Confidential
L : Send later
D : Detail
H : Stored/D. Server
A : RX Notice
□ : Folder

RX Count

000127

\$: Transfer
@ : Forwarding
F : Fine
* : LAN-Fax
N : NGN

P : SEP Code
E : ECM
U : Super Fine
+ : Delivery
✉ : Mail



30 March 2017

By Courier, Fax and Email

GlaxoSmithKline Pte Ltd
150 Beach Road,
#22-00 Gateway West,
Singapore 189720

T +65 6232 8338
F +65 6392 5972
www.gsk.com


1. The BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400 001
Tel No.: +91 22 2272 1233/4
Fax No: +91 22 2272 3121
Email: corp.relations@bseindia.com
2. National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051
Tel No: (022) 26598100 - 8114
Fax No: (022) 26598120
Email: takeover@nse.co.in

Dear Sirs,

Re: Disclosures under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

This is to inform you that we, GlaxoSmithKline Pte Ltd, having our registered office at 150 Beach Road, #21-00, Gateway West, Singapore 189720, are addressing this letter to you for the purpose of disclosing the acquisition of 31,92,238 equity shares held by Castleton Investment Ltd, Mauritius in GlaxoSmithKline Pharmaceuticals Limited which is listed on the BSE Limited and the National Stock Exchange of India Limited. We are enclosing herewith the Form for disclosure of details of acquisition of equity shares in terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Yours faithfully,
For GlaxoSmithKline Pte Ltd



Authorised Signatory
Name: Jason Nicholas Masi, Director

Encl: a/a


Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<u>Acquirer-</u> GlaxoSmithKline Pte Ltd <u>Persons Acting in Concert-</u> (i) Glaxo Group Limited (ii) Eskaylab Limited (iii) Burroughs Welcome International Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes the acquirer forms part of the promoter and promoter group		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	National Stock Exchange (NSE) and Bombay Stock Exchange (BSE)		
Details of the acquisition/ disposal as follows	Number	% w.r.t total share/voting capital wherever applicable(*)	% w.r.t total diluted share /voting capital of the TC(**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights	2,06,09,774	24.33%	24.33%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
c) Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	NIL	NIL	NIL
e) Total (a+b+c+d)	2,06,09,774	24.33%	24.33%
Details of acquisition/sale			
a) Shares carrying voting rights acquired/ old	31,92,238	3.77%	3.77%
b) VRs acquired /sold otherwise than by shares	NIL	NIL	NIL
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	NIL	NIL	NIL
d) Shares encumbered / invoked/released by the acquirer	NIL	NIL	NIL
e) Total (a+b+c+/-d)	31,92,238	3.77%	3.77%

After the acquisition/sale, holding of:			
a) Shares carrying voting rights	2,38,02,012	28.10%	28.10%
b) Shares encumbered with the acquirer	NIL	NIL	NIL
c) VRs otherwise than by shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	NIL
e) Total (a+b+c+d)	2,38,02,012	28.10%	28.10%
Mode of acquisition /sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Off-market inter-se transfer of shares between members of promoter and promoter group		
Date of acquisition /sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	30 March 2017		
Equity share capital / total voting capital of the TC before the said acquisition /sale	Rs. 84,70,30,170		
Equity share capital/ total voting capital of the TC after the said acquisition /sale	Rs. 84,70,30,170		
Total diluted share/voting capital of the TC after the said acquisition	Rs. 84,70,30,170		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.



Signature of the acquirer ~~/seller~~ / Authorised Signatory

Name: Jason Nicholas Masi, Director

Place: Singapore

Date: 30 March 2017